Universal Chimeric Antigen Receptor T-Cell (UCAR-T) Therapy
Showing 1 - 25 of >10,000
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
Not yet recruiting
- Lymphoma
- Chimeric Antigen Receptor
- (no location specified)
Oct 24, 2023
Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy Trial in Suzhou (Targeted IL-13 Ra2 UCAR-T cell
Recruiting
- Advanced Glioma
- Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
- Targeted IL-13 Rα2 UCAR-T cell injection
- Targeted B7-H3 UCAR-T cell injection
-
Suzhou, Jiangsu, ChinaThe Second Affiliated Hospital of Soochow University
Mar 2, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)
Not yet recruiting
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- ThisCART19A
- +3 more
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 28, 2022
Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)
Not yet recruiting
- Lymphoma
- +2 more
- Web Application
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 4, 2022
19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)
Recruiting
- 19 and 22+ B Cell Hematologic Tumors
- 19 and 20+ B Cell Hematologic Tumors
- Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
-
Wuhan, Hubei, ChinaTongji Hospital
Jan 11, 2023
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell
Not yet recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- +5 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2023
Advanced Sarcoma Trial (NKG2D-CAR memory T cell)
Not yet recruiting
- Advanced Sarcoma
- NKG2D-CAR memory T cell
- (no location specified)
Oct 17, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)
Not yet recruiting
- Chronic Graft Versus Host Disease
- +2 more
- Biopsy
- +11 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 7, 2023
B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)
Recruiting
- B-Cell Lymphoma
- +4 more
- 19(T2)28z1xx TRAC T cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023
Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)
Not yet recruiting
- Lymphomas
- B-cell Lymphomas
- JV-213
- Leukapheresis
-
Houston, TexasThe University of Texas M D Anderson Cancer Center
Mar 6, 2023
Advanced Hepatocellular Carcinoma Trial (EU307 CAR-T Cell)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- EU307 CAR-T Cell
- (no location specified)
Mar 13, 2023
Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Biospecimen Collection
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 24, 2023
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem
Not yet recruiting
- Hematologic Malignancy
- +5 more
- autologous hematopoietic stem cells added to planned CAR T
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
May 31, 2023
SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)
Not yet recruiting
- SLE (Systemic Lupus)
- CAR T-cell therapy
-
Bangkok, Please Select, ThailandKing Chulalongkorn Memorial Hospital
Nov 23, 2023
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Large Cell Neuroendocrine Carcinoma of the Lung
- LB2102
- (no location specified)
Jan 10, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia Trial in Saint Louis (Duvelisib)
Recruiting
- Non-hodgkin Lymphoma
- Acute Lymphocytic Leukemia
-
Saint Louis, MissouriWashington University School of Medicine
Jun 30, 2022
Study of Participants Who ReceivedAllogeneic CAR T-Cell Product
Recruiting
- Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
-
Culver City, CaliforniaScience 37, Inc.
Apr 10, 2023
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022